Cytotoxicity induced by docetaxel in human oral squamous cell carcinoma cell lines

In Vivo

Volumn 27, Issue 3, 2013, Pages 321-332

  Iida, Satori ^a   Shimada, Jun ^a   Sakagami, Hiroshi ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Apoptosis; Cytotoxicity; Docetaxel; Oral squamous cell carcinoma cell lines; Serum

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANNEXIN; CASPASE 3; CASPASE 7; DOCETAXEL; PROPIDIUM IODIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CYTOTOXICITY; DNA FRAGMENTATION; FIBROBLAST; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUTH SQUAMOUS CELL CARCINOMA;

EID: 84876925106     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P and Andre S: Preclinical evaluation of docetaxel. Semin Oncol 22: 3-16, 1995.
2. Kaplow R: Innovations in antineoplastic therapy. Review. Nurs Clin North Am 40: 77-94, 2005.
3. Eisenhauer EA and Vermorken JB: The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs 55: 5-30, 1998.
4. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK and VonHoff DD: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245-1251, 1992.
5. De Andres L, Brunet J, Lopez-Pousa A, Burgues J, Vega M, Tabernero JM, Mesia R and Lopez JJ: Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13: 1493-1500, 1995.
6. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, Van den Weyngaert D, Nguyen H, Le Bouder C, Castelijns JA, Kaandera J, De Mulder P and Vermorken JB: Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: A phase I-II feasibility study. Ann Oncol 15: 638-645, 2004.
7. Herskovic A, Martz K, Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
8. Yared JA and Tkaczuk: Update of taxane development: New analogues and new formulations. Drug Des Devel Ther 6: 371-384, 2012.
9. Raisch DW, Campbell W, Garg V, Qureshi ZP, Bookstaver PB, Norris and Bennett CL: Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf 10: 521-528, 2011.
10. Muro K, Hamaguchi A and Ohtsu N: A phase II study of singleagent docetaxel in patients with metastatic esophageal cancer. Annal Oncol 15: 955-959, 2004.
11. Katsumata N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, Aoki D, Susumu N, Kuramoto H, Jobo T, Ueki K, Ueki M, Kohno I, Fujiwara K, Sohda Y and Eguchi F : Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study. Br J Cancer 93: 999-1004, 2005.
12. Braakhuis BJ, Hill BT, Dietel M, Kelland LR, Aapro MS, Zoli W and Lelieveld P: In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res 14: 205-208, 1994.
13. Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskaluk C and El-Rifai W: DARPP-32: A novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 65: 6583-6592, 2005.
14. Tachibana M, Shinagawa Y, Kamamata H, Omotehara F, Horiuchi H, Ohkura Y, Kubota K, Imai Y, Fujibayashi T and Fujimori T: RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections. Anticancer Res 23: 2891-2896, 2003.
15. Kamiya Y and Ohshima T: The Individual cell properties of oral cell carcinoma and p53 tumor suppressor gene mutation. Oral Sci Int 2: 104-117, 2005.
16. Kaneda Y, Shimamoto H, Matsumura K, Arvind R, Zhang S, Sakai E, Omura K and Tsuchida N: Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines. J Med Dent Sci 53: 57-66, 2006.
17. Sakai E and Tsuchida N: Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7: 927-933, 1992.
18. Kashiwazaki Y: Detectability and diagnostic criteria of p53 gene mutations in human oral squamous cell carcinoma using yeast functional assay. Hokkaido Igaku Zasshi 72: 211-224, 1997 (in Japanese).
19. Yanamoto S, Iwamoto T, Kawasaki G, Yoshitomi I, Baba N and Mizuno A: Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 223: 67-76, 2005.
20. Schimming R, Manson KA, Hunter N, Weil M, Kishi K and Milas L: Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 43: 165-172, 1999.
21. Taniguchi T, Takahashi M, Shinohara F, Sato T, Echigo S and Rikiishi H: Involvement of NF-κB and mitochondrial pathways in docetaxel-induced apoptosis of human oral squamous cell carcinoma. Int J Mol Med 15: 667-673, 2005.